Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review
Abstract Background Selective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen’s well-established efficacy, many studies show that most women are not taking up tamoxifen. This systematic literature...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-09-01
|
| Series: | Hereditary Cancer in Clinical Practice |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13053-017-0075-8 |
| _version_ | 1818966801112891392 |
|---|---|
| author | B. Meiser W. K. T. Wong M. Peate C. Julian-Reynier J. Kirk G. Mitchell |
| author_facet | B. Meiser W. K. T. Wong M. Peate C. Julian-Reynier J. Kirk G. Mitchell |
| author_sort | B. Meiser |
| collection | DOAJ |
| description | Abstract Background Selective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen’s well-established efficacy, many studies show that most women are not taking up tamoxifen. This systematic literature review aimed to identify the motivators and barriers to tamoxifen use ‘s amongst high-risk women. Methods Using MEDLINE, PsycINFO, and Embase plus reviewing reference lists of relevant articles published between 1995 and 2016, 31 studies (published in 35 articles) were identified, which addressed high-risk women’s decisions about risk-reducing medication to prevent breast cancer and were peer-reviewed primary clinical studies. Results A range of factors were identified as motivators of, and barriers to, tamoxifen uptake including: perceived risk, breast-cancer-related anxiety, health professional recommendation, perceived drug effectiveness, concerns about side-effects, knowledge and access to information about side-effects, beliefs about the role of risk-reducing medication, provision of a biomarker, preference for other forms of breast cancer risk reduction, previous treatment experience, concerns about randomization in clinical trial protocols and finally altruism. Conclusions Results indicate that the decision for high-risk women regarding tamoxifen use or non-use as a risk-reducing medication is not straightforward. Support of women making this decision is essential and needs to encompass the full range of factors, both informational and psychological. |
| first_indexed | 2024-12-20T13:38:40Z |
| format | Article |
| id | doaj.art-1598ad3f86f54a549e28dbbd6b6d8b63 |
| institution | Directory Open Access Journal |
| issn | 1897-4287 |
| language | English |
| last_indexed | 2024-12-20T13:38:40Z |
| publishDate | 2017-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Hereditary Cancer in Clinical Practice |
| spelling | doaj.art-1598ad3f86f54a549e28dbbd6b6d8b632022-12-21T19:38:52ZengBMCHereditary Cancer in Clinical Practice1897-42872017-09-011511910.1186/s13053-017-0075-8Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature reviewB. Meiser0W. K. T. Wong1M. Peate2C. Julian-Reynier3J. Kirk4G. Mitchell5Prince of Wales Clinical School, UNSWPrince of Wales Clinical School, UNSWPrince of Wales Clinical School, UNSWInstitut Paoli-CalmettesFamilial Cancer Service, Westmead HospitalSir Peter MacCallum Dept of Oncology, University of MelbourneAbstract Background Selective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen’s well-established efficacy, many studies show that most women are not taking up tamoxifen. This systematic literature review aimed to identify the motivators and barriers to tamoxifen use ‘s amongst high-risk women. Methods Using MEDLINE, PsycINFO, and Embase plus reviewing reference lists of relevant articles published between 1995 and 2016, 31 studies (published in 35 articles) were identified, which addressed high-risk women’s decisions about risk-reducing medication to prevent breast cancer and were peer-reviewed primary clinical studies. Results A range of factors were identified as motivators of, and barriers to, tamoxifen uptake including: perceived risk, breast-cancer-related anxiety, health professional recommendation, perceived drug effectiveness, concerns about side-effects, knowledge and access to information about side-effects, beliefs about the role of risk-reducing medication, provision of a biomarker, preference for other forms of breast cancer risk reduction, previous treatment experience, concerns about randomization in clinical trial protocols and finally altruism. Conclusions Results indicate that the decision for high-risk women regarding tamoxifen use or non-use as a risk-reducing medication is not straightforward. Support of women making this decision is essential and needs to encompass the full range of factors, both informational and psychological.http://link.springer.com/article/10.1186/s13053-017-0075-8TamoxifenPreventionRisk-reducing medicationBreast cancerHigh risk |
| spellingShingle | B. Meiser W. K. T. Wong M. Peate C. Julian-Reynier J. Kirk G. Mitchell Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review Hereditary Cancer in Clinical Practice Tamoxifen Prevention Risk-reducing medication Breast cancer High risk |
| title | Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review |
| title_full | Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review |
| title_fullStr | Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review |
| title_full_unstemmed | Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review |
| title_short | Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review |
| title_sort | motivators and barriers of tamoxifen use as risk reducing medication amongst women at increased breast cancer risk a systematic literature review |
| topic | Tamoxifen Prevention Risk-reducing medication Breast cancer High risk |
| url | http://link.springer.com/article/10.1186/s13053-017-0075-8 |
| work_keys_str_mv | AT bmeiser motivatorsandbarriersoftamoxifenuseasriskreducingmedicationamongstwomenatincreasedbreastcancerriskasystematicliteraturereview AT wktwong motivatorsandbarriersoftamoxifenuseasriskreducingmedicationamongstwomenatincreasedbreastcancerriskasystematicliteraturereview AT mpeate motivatorsandbarriersoftamoxifenuseasriskreducingmedicationamongstwomenatincreasedbreastcancerriskasystematicliteraturereview AT cjulianreynier motivatorsandbarriersoftamoxifenuseasriskreducingmedicationamongstwomenatincreasedbreastcancerriskasystematicliteraturereview AT jkirk motivatorsandbarriersoftamoxifenuseasriskreducingmedicationamongstwomenatincreasedbreastcancerriskasystematicliteraturereview AT gmitchell motivatorsandbarriersoftamoxifenuseasriskreducingmedicationamongstwomenatincreasedbreastcancerriskasystematicliteraturereview |